Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CHKA | P35790 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14506909 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL19046575 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL60330 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL14034527 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL27023033 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18228339 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8053 | 1.00 | — | — | |
| SCHEMBL896298 | 1.00 | — | — | |
| SCHEMBL17901788 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8522398 | 0.97 | TDP1 (0.55) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105363-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| US-20230338392-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | ALBIREO AB (SE) | 2023-10-26 | — | — | US | disclosed |
| US-20230330176-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2023-10-19 | — | — | US | disclosed |
| EP-3444238-B1 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | SATO PHARMA (JP) | 2021-12-08 | — | — | EP | disclosed |
| EP-3697410-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | Amgen Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019079578-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| EP-3444238-A2 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | Sato Pharmaceutical Co., Ltd. (JP) | 2019-02-20 | — | — | EP | disclosed |
| US-10000528-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2018-06-19 | — | — | US | disclosed |
| WO-2018071622-A1 | 3-SULFONYL-5-AMINOPYRIDINE-2,4-DIOL APJ AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20180022776-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2018-01-25 | — | — | US | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070105901-A1 | Novel piperidine derivative | MSD K.K. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105901-A1 | Novel piperidine derivative | MSD K.K. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060035155-A1 | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery | SANYO ELECTRIC CO., LTD. (JP) | 2006-02-16 | — | — | US | disclosed |
| EP-0654023-B1 | 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-16 | — | — | EP | disclosed |
| US-5523299-A | ADMINISTERING IN TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1996-06-04 | — | — | US | disclosed |
| EP-0654023-A1 | 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003426-A1 | 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022776-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | TDP1 3715/4885CYP1A2 995/4885ALDH1A1 660/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | TDP1 4530/4885CYP1A2 4222/4885ALDH1A1 1649/4885 |
| US-20230338392-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | SLC10A1, SLC10A2, SLC10A6 | TDP1 4813/4885CYP1A2 961/4885ALDH1A1 1795/4885 |
| US-10000528-B2 | IBAT inhibitors for the treatment of liver diseases | GPR119, SLC10A1, SLC10A2 | TDP1 3715/4885CYP1A2 995/4885ALDH1A1 660/4885 |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | TDP1 4538/4885CYP1A2 844/4885ALDH1A1 1934/4885 |
| US-20070105901-A1 | Novel piperidine derivative | HRH3, OPRM1, OPRK1 | TDP1 3171/4885CYP1A2 1395/4885ALDH1A1 721/4885 |
| US-20230330176-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | SLC10A2, SLC10A1, GPBAR1 | TDP1 4248/4885CYP1A2 1807/4885ALDH1A1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.